Date: 2018-10-01
Type of information: Production agreement
Compound: Furestem-AD®
Company: KangStem Biotech (South Korea) MaSTherCell, (Belgium), a subsidiary of Orgenesis (USA - NY)
Therapeutic area: Technology - Services
Type agreement: manufacturing - bioproduction
Action mechanism:
Disease:
Details:
- • On October 1, 2018, Kangstem Biotech, a biotechnology company specializing in developing cell therapies using mesenchymal stem cells derived from human umbilical cord blood, announced the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of Furestem-AD®). MaSTherCell, a subsidiary of Orgenesis is a cell therapy dedicated Contract Development and Manufacturing Organization (CDMO). MaSTherCell will perform a technology transfer of Furestem-AD’s process and manufacture Furestem-AD for Kangstem’s European clinical trial.
- Kangstem is moving into late phase clinical trials in Korea and strengthened by this expertise, now takes the opportunity to enter into Europe with its innovative cell therapy products.
- The partnership provides Kangstem access to MaSTherCell’s cell therapy manufacturing expertise, capabilities and commercial state of the art new facility. The Agility by Design facility will provide Kangstem with the most efficient clean room set-up for its unique and high-value large-scale manufacturing process. If desired, MaSTherCell’s global facilities further allow Kangstem to easily expand to other continents. This puts Kangstem in a fast-track position to provide its innovative cell therapy products to more patients.
Financial terms:
Latest news:
Is general: Yes
